RxDoctor Payments Data

Robert Snyder, MD

Family Medicine · Pelham, ALNPI 1447369590

Payments from drug & device makers

$15,058in general payments, 2019–2025

Across 1,004 payments — averaging $15.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$2K
  • Lilly USA, LLC$1K
  • GSK$1K
  • Novo Nordisk$907
  • Abbott$716
  • plus $6K from 51 others

What the payments were for

  • Food & beverage$15,049100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)240$2,757
Pfizer111$1,796
Lilly USA, LLC88$1,306
GSK89$1,223
Novo Nordisk54$907
Abbott41$716
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC40$634
AstraZeneca33$521
Johnson & Johnson27$421
Dexcom, Inc.20$406
Exact Sciences23$384
Bayer22$378
Boehringer Ingelheim21$317
E.r. Squibb & Sons, L.L.C.14$229
Merck19$228
Takeda Pharmaceuticals U.S.A., Inc.12$225
Sanofi-aventis U.S. LLC13$225
Biohaven Pharmaceutical Holding Company Ltd.7$163
Biohaven Pharmaceuticals, Inc.9$154
Avanir Pharmaceuticals, Inc.7$131
Amgen7$128
Phathom Pharmaceuticals, Inc.7$126
Eisai Inc.8$125
Xeris Pharmaceuticals, Inc.6$118
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$111
Genentech USA, Inc.6$96
Supernus Pharmaceuticals, Inc.5$94
Esperion Therapeutics, Inc.6$92
Agios Pharmaceuticals, Inc.4$87
Melinta Therapeutics, LLC5$79
Novartis5$72
Otsuka America Pharmaceutical, Inc.3$71
Neos Therapeutics, LP4$65
Astellas Pharma US Inc4$57
Shield Therapeutics Inc3$49
Ironwood Pharmaceuticals, Inc3$47
Antares Pharma, Inc.2$43
Kowa Pharmaceuticals America, Inc.3$42
Amarin Pharma, Inc.3$42
Arbor Pharmaceuticals, Inc.3$37
Aytu Biopharma, Inc.2$35
IBSA Pharma Inc.2$34
Idorsia Pharmaceuticals US Inc2$29
Optinose US, Inc.1$23
Biosense Webster, Inc.1$21
Tris Pharma Inc1$21
Mannkind Corporation1$21
Axsome Therapeutics, Inc.1$21
Jazz Pharmaceuticals Inc.1$21
Bausch Health US, LLC1$20
Vivus LLC1$19
Upsher-smith Laboratories LLC1$18
Corcept Therapeutics1$18
Shire North American Group Inc1$16
Medtronic1$15
Biodelivery Sciences International, Inc.1$14
Adlon Therapeutics L.p.1$14

How this compares

$15,058 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$230,086
Medicare patients
436
Services billed
5,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide187$193,169
EliquisApixaban166$140,845
MounjaroTirzepatide60$65,321
JardianceEmpagliflozin52$65,139
JanuviaSitagliptin Phosphate37$42,290
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$38,818
Janumet XrSitagliptin Phos/Metformin Hcl26$30,724
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog38$26,902
XareltoRivaroxaban33$26,390
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog44$25,350
Breo ElliptaFluticasone/Vilanterol58$23,728
TrulicityDulaglutide14$19,617
Lantus SolostarInsulin Glargine,hum.Rec.Anlog144$16,254
FarxigaDapagliflozin Propanediol22$14,712
LinzessLinaclotide22$14,297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$907$193,169187 claims
PfizerEliquis, Premarin$1,796$146,339190 claims
Lilly USA, LLCMounjaro, Trulicity$1,306$84,93874 claims
MerckJanuvia, Janumet Xr, Dulera$228$77,15575 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,223$69,019125 claims
Boehringer IngelheimJardiance$317$65,13952 claims
Johnson & JohnsonXarelto$421$26,39033 claims
AbbVieLinzess, Synthroid$2,757$24,660159 claims
AstraZenecaFarxiga$521$14,71222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Pelham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →